Immatics (NASDAQ:IMTX) Holdings Decreased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD lowered its stake in Immatics (NASDAQ:IMTX - Free Report) by 29.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,461,592 shares of the company's stock after selling 1,032,910 shares during the quarter. Price T Rowe Associates Inc. MD owned about 2.06% of Immatics worth $17,502,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IMTX. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Immatics by 24.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company's stock worth $163,000 after acquiring an additional 4,477 shares during the period. Guggenheim Capital LLC acquired a new position in shares of Immatics during the 4th quarter valued at $101,000. Aristides Capital LLC bought a new stake in shares of Immatics in the 4th quarter worth $205,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Immatics in the fourth quarter valued at $211,000. Finally, Marshall Wace LLP bought a new position in Immatics during the fourth quarter valued at about $409,000. Institutional investors own 64.41% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a research report on Tuesday, April 1st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Immatics presently has an average rating of "Buy" and an average price target of $16.67.

Immatics Price Performance

Shares of NASDAQ:IMTX traded down $0.13 on Monday, reaching $5.10. 386,018 shares of the company traded hands, compared to its average volume of 654,400. The stock has a market capitalization of $619.91 million, a PE ratio of -7.73 and a beta of 0.87. The company's 50 day moving average is $4.46 and its 200-day moving average is $6.16. Immatics has a fifty-two week low of $3.30 and a fifty-two week high of $13.77.

Immatics (NASDAQ:IMTX - Get Free Report) last announced its earnings results on Thursday, March 27th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.51. The business had revenue of $15.67 million during the quarter, compared to the consensus estimate of $16.16 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. As a group, analysts expect that Immatics will post -0.72 EPS for the current year.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.